A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
Phase 1
Terminated
- Conditions
- Leukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Hemavant Sciences GmbH
- Target Recruit Count
- 127
- Registration Number
- NCT02841540
- Locations
- 🇺🇸
City of Hope, Irvine, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Virginia Cancer Specialist, Fairfax, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath